Guidelines

Japanese rapid/living recommendations on drug management for COVID-19: updated guidelines (July 2022)

Kazuma Yamakawa,1 Ryo Yamamoto,2 Takero Terayama,3 Hideki Hashimoto,4 Tadashi Ishihara,5 Go Ishimaru,6 Haruki Imura,7,8 Hiromu Okano,9 Chihiro Narita,10 Takuya Mayumi,11 Hideto Yasuda,12 Kohei Yamada,13 Hiroyuki Yamada,14 Tatsuya Kawasaki,15 Nobuaki Shime,16 Kent Doi,17 Moritoki Egii,18 Hiroshi Ogura,19 Morio Aihara,20 Shigeki Kushimoto,21 Osamu Nishida,22 and Special Committee of the Japanese Clinical Practice Guidelines for the Management of Sepsis and Septic Shock 2020 (J-SSCG 2020), the COVID-19 Task Force

1Department of Emergency and Critical Care Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan, 2Department of Emergency and Critical Care Medicine, Keio University School of Medicine, Tokyo, Japan, 3Department of Psychiatry, School of Medicine, National Defense Medical College, Tokorozawa, Japan, 4Department of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan, 5Department of Emergency and Critical Care Medicine, Juntendo University Urayasu Hospital, Urayasu, Japan, 6Department of General Internal Medicine, Soka Municipal Hospital, Soka, Japan, 7Department of Infectious Diseases, Rakuwakai Otowa Hospital, Kyoto University, Kyoto, Japan, 8Department of Health Informatics, School of Public Health, Kyoto University, Kyoto, Japan, 9Department of Critical Care and Emergency Medicine, National Hospital Organization Yokohama Medical Center, Yokohama, Japan, 10Department of Emergency Medicine and Intensive Care Medicine, Shizuoka General Hospital, Shizuoka, Japan, 11Department of Internal Medicine, Kanazawa Municipal Hospital, Kanazawa, Japan, 12Department of Emergency and Critical Care Medicine, Jichi Medical University Saitama Medical Center, Saitama, Japan, 13Department of Traumatology and Critical Care Medicine, National Defense Medical College, Tokorozawa, Japan, 14Department of Primary Care and Emergency Medicine, Kyoto University Hospital, Kyoto, Japan, 15Department of Pediatric Critical Care, Shizuoka Children’s Hospital, Shizuoka, Japan, 16Department of Emergency and Critical Care Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan, 17Department of Emergency and Critical Care Medicine, Graduate School of Medical Science, The University of Tokyo, Tokyo, Japan, 18Department of Anesthesia, Kyoto University Hospital, Kyoto, Japan, 19Department of Traumatology and Acute Critical Medicine, Osaka University Medical School, Suita, Japan, 20Department of Gastroenterology and Hematology, Hiroshi University Graduate School of Medicine, Hirosaki, Japan, 21Division of Emergency and Critical Care Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan, and 22Department of Anesthesiology and Critical Care Medicine, Fujita Health University School of Medicine, Toyoake, Japan

Background: Coronavirus disease (COVID-19), an infectious disease caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread worldwide since early 2020, and there are still no signs of resolution. The Japanese Clinical Practice Guidelines for the Management of Sepsis and Septic Shock (J-SSCG) 2020 Special Committee created the Japanese Rapid/Living recommendations on drug management for COVID-19 using the experience of creating the J-SSCG.

Methods: The Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) approach was used to determine the certainty of the evidence and strength of recommendations. The first edition of this guideline was released on September 9, 2020, and this is the revised edition (version 5.0; released on July 15, 2022). Clinical questions (CQs) were set for the following 10 drugs: favipiravir (CQ1), remdesivir (CQ2), corticosteroids (CQ4), tocilizumab (CQ5), anticoagulants (CQ7), baricitinib (CQ8), casirivimab/имдевимаб (CQ9-1), sotrovimab (CQ9-2), molnupiravir (CQ10), and nirmatrelvir/риритонавир (CQ11).

Recommendations: Favipiravir is not suggested for all patients with COVID-19 (GRADE 2C). Remdesivir is suggested for patients with mild COVID-19 who do not require oxygen, and patients with moderate COVID-19 requiring supplemental oxygen/hospitalization...
Corticosteroids are recommended for moderate and severe COVID-19 (GRADE 1B, 1A). However, their administration is not recommended for mild COVID-19 (GRADE 1B). Tocilizumab is suggested for moderate and severe COVID-19 (GRADE 2B, 2C). Anticoagulant administration is recommended for moderate and severe COVID-19 (Good Practice Statement). Baricitinib is suggested for moderate and severe COVID-19 (both GRADE 2C). Casirivimab/imdevimab and sotrovimab are recommended for mild COVID-19 (both GRADE 2C). Molnupiravir and nirmatrelvir/ritonavir are recommended for mild COVID-19 (both GRADE 2C). SARS-CoV-2 mutant strains emerge occasionally, and each time, the treatment policy at clinics is forced to change drastically. We ask healthcare professionals in the field to refer to the recommendations in these guidelines and use these to keep up to date with COVID-19 epidemiological information.

Key words: Coronavirus, GRADE approach, MAGICapp, practice guideline, SARS-CoV-2

BACKGROUND

CORONAVIRUS DISEASE 2019 (COVID-19), an infectious disease caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that developed at the end of 2019, has spread worldwide since the beginning of 2020, and there are still no signs of resolution. Initially, COVID-19 severely affected some elderly individuals and those with underlying diseases, and its lethal course became a socially critical problem. The main cause of COVID-19 pneumonia is severe respiratory failure caused by pneumonia. At the same time, clarification of its pathophysiology has progressed, including the intertwining of various complex pathologies, such as coagulation disorders and multiorgan dysfunction. In addition, various specific therapeutic agents, such as antiviral drugs, anti-inflammatory drugs, and antibody therapeutics, have been developed and used in clinical settings. Stringent policies have been implemented to control the infectious disease, such as lockdowns worldwide. Medical practice to save the lives of patients with COVID-19 has been carried out day and night in the medical field.

In Japan, the replacement of omicron strains began in early 2022, and the status of antibody treatment and antiviral drugs has drastically changed. Against the background of the magnitude and urgency of social impact, clinical evidence of various qualities has been published daily regarding various drug therapies. The Japanese Clinical Practice Guidelines for the Management of Sepsis and Septic Shock (J-SSCG) 2020 Special Committee, jointly organized by the Japanese Society of Intensive Care Medicine and the Japanese Association for Acute Medicine, made use of their experience to create the J-SSCG based on the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) system. We aimed to create a special edition specializing in COVID-19 drug management to provide the latest information on the websites of both societies and support evidence-based medical care. The first edition of this clinical practice guideline was released on September 9, 2020, and the English edition was previously published.1,2 This document is the revised 5.0 edition (released on July 15, 2021; Table 1, Fig. 1).

OVERVIEW AND BASIC PRINCIPLES OF THIS CLINICAL PRACTICE GUIDELINE

Purpose of the guideline

COVID-19 IS A serious disease that affects all age groups. It is of great social significance to create reliable clinical practice guidelines to support clinical practice. A variety of clinical evidence exists in the preprint server articles. However, clinicians have limited time to obtain high-quality information. This clinical practice guideline aims to support appropriate decision-making in COVID-19 clinical practice.

Target patient population for the recommendations

The target population was adult patients with COVID-19. It included all patients, including mildly ill patients who were undergoing medical treatment outside the medical institution (home and hotels), moderately ill patients who required supplemental oxygen or hospitalization, and severely ill patients who required intensive care management.

Participation of representatives of relevant expert groups and external evaluation by experts

A task force within the J-SSCG 2020 Special Committee was selected to work on this clinical practice guideline. All Task Force members were physicians familiar with the treatment of sepsis and COVID-19. One core working member was commissioned as an expert on the GRADE approach adopted in this clinical practice guideline.

© 2022 The Authors. Acute Medicine & Surgery published by John Wiley & Sons Australia, Ltd on behalf of Japanese Association for Acute Medicine.
| Clinical question (CQ)                                                                 | Recommendation                                                                                      |
|-------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| **CQ1** Should favipiravir be administered to patients with COVID-19?                | • We suggest against favipiravir administration to all patients with COVID-19 (weak recommendation/low certainty of evidence: GRADE 2C) |
| **CQ2** Should remdesivir be administered to patients with COVID-19?                | • We suggest remdesivir administration to patients with mild COVID-19 who do not require oxygen and patients with moderate COVID-19 requiring oxygen/hospitalization (weak recommendation/moderate certainty of evidence: GRADE 2B) |
|                                                                                      | • We suggest against remdesivir administration to patients with severe COVID-19 requiring mechanical ventilation/intensive care (weak recommendation/low certainty of evidence: GRADE 2C) |
| **CQ4-1** Should corticosteroid be administered to COVID-19 patients?              | • We recommend against corticosteroid administration to patients with mild COVID-19 who do not require oxygen (strong recommendation/moderate certainty of evidence: GRADE 1B) |
|                                                                                      | • We recommend corticosteroid administration to patients with moderate COVID-19 requiring oxygen/hospitalization (strong recommendation/moderate certainty of evidence: GRADE 1B) |
|                                                                                      | • We recommend corticosteroid administration to patients with severe COVID-19 requiring mechanical ventilation/intensive care (strong recommendation/high certainty of evidence: GRADE 1A) |
| **CQ4-2** Should corticosteroid pulse therapy be administered to patients with moderate/severe COVID-19? | • We have not made clear recommendations on corticosteroid pulse therapy to patients with moderate COVID-19 requiring oxygen administration/hospitalization or patients with severe COVID-19 requiring mechanical ventilation/intensive care (no recommendation) |
| **CQ5** Should tocilizumab be administered for COVID-19 patients?                  | • We have not made a clear recommendation on tocilizumab administration to patients with mild COVID-19 who do not require oxygen (no recommendation) |
|                                                                                      | • We suggest tocilizumab administration to patients with moderate COVID-19 requiring oxygen/hospitalization (weak recommendation/moderate certainty of evidence: GRADE 2B) |
|                                                                                      | • We suggest tocilizumab administration to patients with severe COVID-19 requiring mechanical ventilation/intensive care (weak recommendation/low certainty of evidence: GRADE 2C) |
| **CQ7-1** Should anticoagulants be administered to patients with COVID-19?          | • We suggest against anticoagulant administration to patients with mild COVID-19 who do not require oxygen (weak recommendation/low evidence: GRADE 2C) |
|                                                                                      | • We recommend anticoagulant administration to patients with moderate COVID-19 requiring oxygen administration/hospitalization and patients with severe COVID-19 requiring mechanical ventilation/intensive care (good practice statement) |
| **CQ7-2** What doses of anticoagulants should be administered to patients with COVID-19? | • We suggest therapeutic doses of anticoagulant administration to patients with moderate COVID-19 requiring oxygen administration/hospitalization (weak recommendation/low certainty of evidence: GRADE 2C) |
|                                                                                      | • We suggest prophylactic doses of anticoagulant administration to patients with severe COVID-19 requiring ventilator management/intensive care (weak recommendation/moderate certainty of evidence: GRADE 2B) |
| **CQ8** Should baricitinib be administered to patients with COVID-19?              | • We have not made a clear recommendation on baricitinib administration to patients with mild COVID-19 who do not require oxygen (no recommendation) |
|                                                                                      | • We suggest baricitinib administration to patients with moderate COVID-19 requiring oxygen/hospitalization (weak recommendation/low certainty of evidence: GRADE 2C) |
|                                                                                      | • We suggest baricitinib administration to patients with severe COVID-19 requiring mechanical ventilation/intensive care (weak recommendation/low certainty of evidence: GRADE 2C) |
| **CQ9-1** Should casirivimab/imdevimab be administered to patients with COVID-19? | • We suggest casirivimab/imdevimab administration to patients with mild COVID-19 who do not require oxygen (weak recommendation/low certainty of evidence: GRADE 2C) |
|                                                                                      | • We have not made a clear recommendation on casirivimab/imdevimab administration to patients with moderate COVID-19 requiring oxygen/hospitalization or patients with severe COVID-19 requiring mechanical ventilation/intensive care (no recommendation) |
Devising ways to reflect the values and preferences of the target group

No qualitative research on the values and preferences of patients was conducted.

Users of this clinical practice guideline

This includes all medical professionals, such as physicians, nurses, pharmacists, physiotherapists, clinical engineers, pharmacists, and registered dietitians who are engaged in or involved in COVID-19 medical care.

Dissemination of this clinical practice guideline

These clinical practice guidelines will be published free of charge on the websites of the Japanese Society of Intensive Care Medicine and the Japanese Association for Acute Medicine. In addition, the latest version will be released on the Making GRADE the Irresistible Choice (MAGIC) Authoring and Publication Platform (MAGICapp) and provided in a form easy to use in clinical settings.

Funding

This clinical practice guideline was prepared with funding from the Japanese Society of Intensive Care Medicine and Japanese Association for Acute Medicine. None of the members received any reward for their work.

Transparency in creating clinical practice guidelines

Audit committee members were appointed to conduct an internal peer review of various work processes in real-time. The economic conflict of interest was applied and disclosed for 3 years from 2017, in accordance with the guidance on the criteria for participation in the formulation of clinical practice guidelines of the Japanese Association of Medical Sciences.

Revision schedules

Updates will be made accordingly as evidence is modified or added. The period for continuing revisions will last until the COVID-19 epidemic period ends. The decision to end the revision will be made by the board of directors of both the academic societies.

METHOD OF PREPARING THIS CLINICAL PRACTICE GUIDELINE

The Japanese Rapid/Living recommendations on drug management for COVID-19 were prepared in accordance with the GIN-McMaster guideline development...
Fig. 1. Visual summary of recommendations on drug management for COVID-19. The recommendations for each medication are visually summarized. For each medication, recommendations are provided depending on the severity of COVID-19: mild, moderate, or severe. GPS, good practice statement.
checklist (extension of the Guideline Development Checklist for rapid guidelines), and the GRADE approach was adopted to determine the strength and certainty of the evidence and recommendations.

**Scope and clinical question planning**

According to the current situation of COVID-19 medical care in Japan, a drug with high clinical importance was selected as a clinical question (CQ) among the drug therapies available in clinical practice. The selection was decided by consensus of the Task Force members. The agreement criteria were acceptance by two-thirds or more of all participating members, and the degree of disagreement was evaluated using the Rand/UCLA method.

**PICOT settings for recommendations**

For a fully formulated comparative effectiveness systematic review topic as the basis of recommendations, key questions in their final form specify the patient populations, interventions, comparators, outcome measures of interest, and timing (PICOT) to be addressed in the review.

**Target patient population**

The target population was adult patients with COVID-19. It included all patients, including mildly ill patients who were undergoing medical treatment outside the medical institution (home and hotels), moderately ill patients who required supplemental oxygen or hospitalization, and severely ill patients who required intensive care management. The COVID-19 severity classification is defined as shown in Table 2 with reference to the Ministry of Health, Labor, and Welfare “Clinical Management of Patients with COVID-19.” As a general rule, recommendations were made according to severity and, if necessary, presented for each target subgroup depending on the CQ.

**Intervention treatment**

The target drugs were selected as appropriate, taking into consideration the state of evidence collection and social conditions at that time, through discussions with and voting of the governing committee and Task Force.

**Comparison**

Only direct (head-to-head) comparison was included in this practice guideline: intervention treatment versus standard treatment (or conventional care, placebo treatment) of interest.

**Outcome**

The importance of outcomes was graded using a 1–9-point scale (9 being most patient-important). Ultimately, we set three significant patient outcomes (i.e., a rated scale of 7–9) for making recommendations: all-cause mortality, clinical improvement, and serious adverse events.

**Time frame**

As a general rule, the outcome was measured 28 days after the intervention; however, depending on the evidence obtained, if there were no (or few) outcomes after 28 days, we also adopted those after 7 or 14 days.

**GRADE-ADOLOPMENT for the development of practical and trustworthy guidelines**

The “GRADE-ADOLOPMENT” approach to guideline production combines adoption, adaptation, and, as needed,

| Table 2. COVID-19 severity classification in this guideline |
|-------------------------------------------------------------|
| Severity | Oxygen saturation | Clinical condition | Place of medical treatment |
|----------|-------------------|--------------------|---------------------------|
| Mild     | SpO_2 > 93%       | No respiratory symptoms | Need medical treatment outside the medical institution (home and hotels) |
|          |                   | Cough only, no shortness of breath |                           |
| Moderate | SpO_2 ≤ 93%       | Shortness of breath, symptoms of pneumonia | Need hospitalization at a medical institution |
|          |                   | Oxygen administration required |                           |
| Severe   |                   | Need a mechanical ventilator | Need treatment in the intensive care unit |

SpO_2, saturated oxygen in arterial blood.
de novo development of recommendations. The information sources of existing evidence synthesis that we used are the COVID-living NMA (https://covid-nma.com/living-data/index.php) and PubMed Central. We also included non-peer-reviewed preprint server articles. Conference abstracts and press releases were excluded. This version 5.0 is created based on the evidence obtained as of May 31, 2022.

**Evaluation of the certainty of the body of evidence using GRADE**

**Definition and evaluation method for the certainty of the evidence**

We assessed the certainty of evidence using the GRADE approach and rated the certainty for each outcome as high (A), moderate (B), low (C), or very low (D) based on the following eight factors of GRADE: five factors might lead to a rating down of the certainty of evidence (risk of bias [RoB], inconsistency, indirectness, imprecision, and publication bias), and three factors might lead to the rating up (large effect, plausible confounding, and dose–response gradient). For individual studies and the overall evidence of RoB, Cochrane RoB 2.06 was used.

**Calculation of net effect estimates for overall outcomes (net effect estimate)**

The GRADE Working Group introduced the concept of certainty of net benefit to clarify and simplify the methodology to report and assess the balance of benefits and harms in the context of fully contextualizing the certainty of evidence across outcomes. Specifically, it can be predicted that the three critical outcomes set in this guideline are not equally patient-important. Therefore, to evaluate the balance between benefit and harm, the effects of these outcomes were integrated by considering the difference in importance (utility value), and the importance-adjusted net effect estimate was then calculated. The overall imprecision across outcomes was assessed based on the magnitude and confidence intervals of the calculated net effect estimates.

**Formulation of recommendations and consensus building**

The Panel Committee determined the direction and strength of recommendations using the GRADE/DECIDE Evidence-to-Decision frameworks, which include four key criteria (certainty of evidence, balance of benefits and harms, patient values and preferences, and cost-resource use), as well as acceptability and feasibility. According to GRADE/Evidence-to-Decision, the Panel graded the strength of the recommendations as strong or conditional (for or against the intervention of interest). If the overall certainty of the evidence across the critical outcome was very low, it was not recommended. The panel committee voted and reached a consensus using the Rand/UCLA appropriateness method.4 For the CQ that handled extremely common themes and for which randomized controlled trials (RCTs) were theoretically impossible, we made recommendations using the decision algorithm of good practice statement.9

**Prompt disclosure of recommendations**

For the rapid publication of recommendations, MAGICapp, designed by MAGIC, was utilized, which supports efficient guideline writing, dissemination, dynamic updating, and consultation decision-making in the medical field.10

**RECOMMENDATIONS AND THEIR RATIONALES**

**CQ1 Should favipiravir be administered to patients with COVID-19?**

**Recommendation**

• We suggest against favipiravir administration to all patients with COVID-19 (weak recommendation/low certainty of evidence: GRADE 2C).

**Background**

Favipiravir is an antiviral drug developed for the treatment of new or re-emerging influenza virus infections. Its effect on RNA virus is expected due to the selective inhibition of RNA polymerase by the triphosphorylated product converted in vivo. Although the drug is expected to be effective against COVID-19, its efficacy has not yet been determined, and it is likely to have great clinical significance in planning CQs.

**Recommendation rationale**

- Balance between benefits and harm

There were 11 RCTs11–23 with adopted evidence. Point estimates were not expected to have a clinically meaningful effect on clinical improvement at 28 days (an increase of 14 per 1,000). Serious adverse events were unlikely to occur; however, the previously mentioned teratogenicity should be noted. The assessment of mortality outcomes was inadequate because the patients targeted for RCTs predominantly had mild symptoms.

Based on the above statements on the balance between benefit and harm, it was determined that favipiravir administration was not beneficial for all patients with COVID-19.
CQ2 Should remdesivir be administered to patients with COVID-19?

Recommendation

- We suggest remdesivir administration to patients with mild COVID-19 who do not require oxygen and patients with moderate COVID-19 requiring oxygen/hospitalization (weak recommendation/moderate certainty of evidence: GRADE 2B).
- We suggest against remdesivir administration to patients with severe COVID-19 requiring mechanical ventilation/intensive care (weak recommendation/low certainty of evidence: GRADE 2C).

Background Remdesivir, developed as a therapeutic drug for Ebola hemorrhagic fever and Marburg virus infection, has been shown to have antiviral activity against single-stranded RNA viruses such as Middle East respiratory syndrome (MERS) virus, severe acute respiratory syndrome (SARS) virus, and SARS-CoV-2. It is a drug whose therapeutic target is RNA-dependent RNA polymerase, which is essential for self-replication of RNA viruses. In Japan, it was approved as a therapeutic drug for the novel coronavirus infection on May 7, 2020. Therefore, it is considered to be of great clinical significance in the formulation of this CQ.

Recommendation rationale

- Balance between benefits and harm

There were seven RCTs31-39 with the adopted evidence. Mild cases were expected to have a small effect on all-cause mortality (no difference per 1,000) and improvement in clinical symptoms (increase of 47 per 1,000). In moderate cases, moderate effects were expected for all-cause mortality (decrease of 17 per 1,000) and improvement in clinical symptoms (increase of 68 per 1,000) (Fig. 2). In severe cases, there was no expected effect on all-cause mortality (increase of 47 per 1,000) or improvement in clinical symptoms (decrease of 20 per 1,000). There was no increase in the incidence of serious adverse events (decrease of 26 per 1,000) of any severity.

Based on the above, it was determined that the benefits of remdesivir administration outweigh those of mild and moderate diseases. However, it was determined that the harm caused by the administration of remdesivir outweighed the benefits for critically ill patients.

CQ4-1 Should corticosteroids be administered to patients with COVID-19?

Recommendation

- We recommend against corticosteroid administration to patients with mild COVID-19 who do not require oxygen (strong recommendation/moderate certainty of evidence: GRADE 1B).
- We recommend corticosteroid administration to patients with moderate COVID-19 requiring oxygen/hospitalization (strong recommendation/moderate certainty of evidence: GRADE 1B).
- We recommend corticosteroid administration to patients with severe COVID-19 requiring mechanical ventilation/intensive care (strong recommendation/high certainty of evidence: GRADE 1A).

Background Various types of corticosteroids have been used for the treatment of various diseases for a long time. It is speculated that the mechanism by which COVID-19 becomes severe is that organ damage occurs due to an excessive immune response in the host, such as viral pneumonia (H5N1 influenza, SARS, and H1N1 influenza) that was prevalent in the past. Corticosteroids are expected to attenuate immune responses. Therefore, CQ planning is considered to have a significant clinical significance.

Recommendation rationale

- Balance between benefits and harm

There were nine RCTs31-39 with the adopted evidence. In the mild COVID-19 group, one RCT with 1,535 cases was adopted, and no effect was expected on all-cause mortality. No data were available for clinical improvement.
or any serious adverse events. In the moderate COVID-19 group, four RCTs with 4,293 cases were adopted, and a moderate effect was expected in all-cause mortality and clinical improvement (decrease of 156 per 1,000). No data were available for serious adverse events. In the severe COVID-19 group, seven RCTs with 2,047 cases were adopted, and it was expected to have a great effect on all-cause mortality and clinical improvement (decrease of 279 per 1,000). There were a few serious adverse events.

Therefore, regarding the balance between benefit and harm, it was judged that the benefit was superior in patients with moderate/severe COVID-19, and the harm was greater in patients with mild COVID-19.  

**Certainty of evidence**  
Only one outcome was adopted for mild COVID-19, and the overall certainty of evidence was “moderate.” It was rated as “moderate” in the moderate COVID-19 and “high” high for severe COVID-19.

**CQ4-2 Should corticosteroid pulse therapy be administered to patients with moderate/severe COVID-19?**

**Recommendation**

- We have not made clear recommendations on corticosteroid pulse therapy to patients with moderate COVID-19.
requiring oxygen administration/hospitalization and to patients with severe COVID-19 requiring mechanical ventilation/intensive care (no recommendation).

**Background** Corticosteroid pulse therapy is a treatment method that has been investigated for its effectiveness in patients with viral pneumonia, such as SARS, and in patients with extremely severe respiratory failure, such as acute respiratory distress syndrome, to whom high-dose corticosteroids are administered. It is a treatment method that sets it apart from other corticosteroid therapies, and a new CQ was developed for patients with severe illness.

**Recommendation rationale**
- Balance between benefits and harm

---

We adopted two RCTs for hospitalized patients.\(^4,11\) These RCTs determined that the target patients were admitted to the intensive care unit but were not ventilated. As such, it was classified as “moderate” in this guideline. Three hundred sixty-three cases were adopted, and a moderate effect was expected in all-cause mortality at the time of discharge (decrease of 104 per 1,000). No data were available for clinical improvement, and serious adverse events were expected to have a slight effect (25 per 1,000 reductions). However, the quality of the RCTs was low, and the overall certainty of the evidence was very low. Therefore, the balance between these effects was unclear.

- **Certainty of evidence**
  The overall certainty of evidence was set to “very low.”

---

© 2022 The Authors. *Acute Medicine & Surgery* published by John Wiley & Sons Australia, Ltd on behalf of Japanese Association for Acute Medicine.
CQ5 Should tocilizumab be administered to patients with COVID-19?

**Recommendation**

- We have not made a clear recommendation on tocilizumab administration to patients with mild COVID-19 who do not require oxygen (no recommendation).
- We suggest tocilizumab administration to patients with moderate COVID-19 requiring oxygen/hospitalization (weak recommendation/moderate certainty of evidence: GRADE 2B).
- We suggest tocilizumab administration to patients with severe COVID-19 requiring mechanical ventilation/intensive care (weak recommendation/low certainty of evidence: GRADE 2C).

**Background** Increased production of inflammatory cytokines, including interleukin 6 (IL-6), has been reported to be associated with disease progression in patients with COVID-19. Tocilizumab, an IL-6 receptor antagonist, is expected to suppress the action of inflammatory cytokines in patients with COVID-19 and improve their prognosis. Many clinical studies have been conducted; however, its effectiveness has not been clarified. This CQ was formulated because it is likely to have great clinical significance as a candidate therapeutic drug for COVID-19.

**Recommendation rationale**

- Balance between benefit and harm
  
  In 15 RCTs42–56 with 8,318 cases of severe/moderate COVID-19, tocilizumab for moderate COVID-19 was expected to decrease all-cause mortality by 32 per 1,000 and increase clinical improvement by 35 per 1,000 on day 28. For severe COVID-19, a decrease of 16 per 1,000 was expected for all-cause mortality at 28 days, and an increase of 12 per 1,000 was expected for improvement of clinical symptoms (Fig. 4). The incidence of serious adverse events did not increase in the severe/moderate COVID-19 cases (18 per 1,000 decrease).

  Based on the above statements, it was determined that the benefit of tocilizumab administration would outweigh the harm in patients with severe/moderate COVID-19. The balance between the benefits and harms of tocilizumab was undeterminable in patients with mild COVID-19.

- Certainty of evidence
  
  The certainty of evidence for each outcome was “moderate” in patients with moderate COVID-19 and “low” or “moderate” in patients with severe COVID-19. Considering the net effect estimate, the overall certainty of evidence was judged to be “moderate” for patients with moderate COVID-19 and “low” for those with severe COVID-19.

CQ7-1 Should anticoagulants be administered to patients with COVID-19?

**Recommendation**

- We suggest against anticoagulant administration to patients with mild COVID-19 who do not require oxygen (weak recommendation/low certainty of evidence: GRADE 2C).
- We recommend anticoagulant administration to patients with moderate COVID-19 requiring oxygen administration/hospitalization and to patients with severe COVID-19 requiring mechanical ventilation/intensive care (good practice statement).

**Background** Coagulopathy due to angiopathy associated with a viral infection is considered a pathological condition of COVID-19. Pulmonary embolism is one of the causes of death from COVID-19, and prevention of thrombus formation is expected to lead to improvement in patient prognosis. Given the clinical significance of examining the effectiveness of anticoagulant therapy, including the dose, this CQ was formulated.

**Recommendation rationale**

- Balance between benefit and harm
  
  There was one RCT57 with adopted evidence for patients with mild COVID-19. Anticoagulant therapy in patients with mild COVID-19 had an absolute effect of an increase of 3 per 1,000 for all-cause deaths and cardiovascular events, 24 per 1,000 for medical visits within 45 days, and 53 per 1,000 for all bleeding events (Fig. 5). Thus, it was determined that the benefit of not receiving anticoagulant therapy exceeded that of receiving it.

  Multiple RCTs related to anticoagulant therapy in patients with moderate-to-severe COVID-19 have been reported, but no RCT comparing the presence or absence of anticoagulant therapy has been reported. As far as the comparative control groups in the RCTs reported so far have been evaluated, the discussion is premised on providing anticoagulant therapy. As such, we believe that the implementation of anticoagulant therapy is a good practice statement.

- Certainty of evidence
  
  Evidence for all-cause mortality and cardiovascular events, visits to medical institutions within 45 days, and the combined outcome of all bleeding events was determined to be “low” in patients with mild COVID-19.
CQ7-2 What doses of anticoagulants should be administered to patients with COVID-19?

**Recommendation**

- We suggest therapeutic doses of anticoagulant administration to patients with severe COVID-19 requiring oxygen administration/hospitalization (weak recommendation/low certainty of evidence: GRADE 2C).
- We suggest prophylactic doses of anticoagulant administration to patients with COVID-19 requiring ventilator management/intensive care (weak recommendation/moderate certainty of evidence: GRADE 2B).

**Background** Anticoagulant therapies have been tested using two administration methods: a prophylactic dose and a therapeutic dose for thrombosis. To date, multiple RCTs have compared prophylactic and therapeutic doses in patients with moderate and severe COVID-19. Therefore, this CQ was formulated as follows.

**Recommendation rationale**

- Balance between benefit and harm
- There are five RCTs including 3,365 patients with the adopted evidence for patients with moderate COVID-19 (Fig. 5). In studies comparing therapeutic and prophylactic doses, the absolute effect of anticoagulant therapy on all-cause mortality in patients with moderate COVID-19 was increased by 2 per 1,000, organ support-free at day 28 was increased by 38 per 1,000, and severe bleeding was increased by 12 per 1,000. Based on the above, it was...
determined that the benefit of the therapeutic dose of anticoagulant therapy would outweigh the harm in patients with moderate COVID-19.

There are three RCTs including 1,123 patients with the adopted evidence for patients with severe COVID-19. In studies comparing the therapeutic and prophylactic doses of anticoagulant therapy for patients with severe COVID-19, the absolute effect of all-cause mortality was 57 fewer per 1,000 patients, and severe bleeding was 20 more per 1,000 patients. The adjusted odds ratio of the therapeutic dose to the prophylactic dose for organ support-free days up to day 21 was 0.83 (0.67–1.03). Based on the above, it was determined that the benefit of prophylactic doses of anticoagulant therapy would outweigh the harm in severe patients.

### Certainty of evidence

Evidence for all-cause mortality, organ support-free status, and severe bleeding outcomes was assessed as “possible net harm” in mild COVID-19 and “possible net benefit” in moderate COVID-19 based on the magnitude of the point estimate and 95% confidence intervals of the calculated net effect estimates. Abbreviation: CoE, certainty of evidence; GRADE, Grades of Recommendation, Assessment, Development, and Evaluation; UFH, unfractionated heparin.

### CQ8 Should baricitinib be administered to patients with COVID-19?

**Recommendation**

- We have not made a clear recommendation on baricitinib administration to patients with mild COVID-19 who do not require oxygen (no recommendation).
We suggest baricitinib administration to patients with moderate COVID-19 requiring oxygen/hospitalization (weak recommendation/low certainty of evidence: GRADE 2C).

We suggest baricitinib administration to patients with severe COVID-19 requiring mechanical ventilation/intensive care (weak recommendation/low certainty of evidence: GRADE 2C).

**Background**

The aggravation of COVID-19 has been attributed to excessive immune response. Baricitinib is an orally administered selective inhibitor of Janus kinases 1 and 2. It suppresses excessive immune responses by suppressing the intracellular cytokine signaling pathway. In Japan, it was approved for use in combination with remdesivir in cases requiring supplemental oxygen on April 23, 2021. The efficacy of baricitinib has not yet been determined and it is considered to have great clinical significance in planning CQs.

**Recommendation rationale**

- **Balance between benefit and harm**

In three RCTs\(^6^5 - ^6^7\) with 2,659 cases of severe/moderate COVID-19, baricitinib for moderate COVID-19 was expected to decrease all-cause mortality by 42 per 1,000 and increase clinical improvement by 33 per 1,000 (Fig. 6). The incidence of serious adverse events did not increase (decrease of 40 per 1,000). The net effect estimates were 199 fewer per 1,000 when the weighted importance of mortality

---

**Fig. 6.** Recommendations of baricitinib for management for COVID-19 (CQ8). We have not made a clear recommendation on baricitinib administration to mild COVID-19 patients and suggest baricitinib administration to patients with moderate and severe COVID-19. Net effect estimates of baricitinib in patients with moderate and severe COVID-19 were calculated using the effects of each outcome, in which the importance of mortality was considered to be three times higher than those of other outcomes. Overall imprecisions across outcomes were assessed as “net benefit,” based on the magnitude of point estimate and 95% confidence intervals of the calculated net effect estimates. Abbreviations: CoE, certainty of evidence; GRADE, Grades of Recommendation, Assessment, Development, and Evaluation; SAE, severe adverse events.
outcomes was tripled over other outcomes, and the directionality was the same as when it was not weighted. Therefore, we believe that the benefits outweighed the harm.

Baricitinib for severe COVID-19 was expected to decrease all-cause mortality by 88 per 1,000 and increase clinical improvement by 91 per 1,000. The incidence of serious adverse events did not increase (decrease of 66 per 1,000). The net effect estimates were 421 fewer per 1,000 when the weighted importance of mortality outcomes was tripled over other outcomes, and the directionality was the same as when it was not weighted. Therefore, we believe that the benefits outweighed the harm.

- **Certainty of evidence**
  
  The certainty of evidence at each outcome was “low” or “very low” in moderate/severe COVID-19. Considering the net effect estimate, the overall certainty of the evidence was determined as “low” in patients with moderate/severe COVID-19.

- **Others (tolerability and feasibility)**
  
  Baricitinib has been approved in Japan for the treatment of COVID-19 in combination with remdesivir. The efficacy of the combined use of the three drugs (baricitinib, remdesivir, and steroid) has not been fully evaluated.

### Q9-1 Should casirivimab/imdevimab be administered to patients with COVID-19?

**Recommendation**

- We suggest casirivimab/imdevimab administration to patients with mild COVID-19 who do not require oxygen (weak recommendation/low certainty of evidence: GRADE 2C).
- We have not made a clear recommendation on casirivimab/imdevimab administration to patients with moderate COVID-19 requiring oxygen/hospitalization or patients with severe COVID-19 requiring mechanical ventilation/intensive care (no recommendation).

**Background** Casirivimab/imdevimab is an antibody cocktail therapy that simultaneously administers two monoclonal antibodies against SARS-CoV-2 and is expected to be effective against COVID-19. However, its effectiveness has not been established; hence, we formulated this CQ.

**Recommendation rationale**

- Balance between benefit and harm

  In 5,665 cases of mild COVID-19 in four RCTs,68–71 all-cause mortality was expected to decrease by 9 per 1,000, clinical improvement was expected to increase by 29 per 1,000, and the incidence of serious adverse events did not increase (decrease of 30 per 1,000; Fig. 7). In all outcomes, the intervention group showed benefits. We determined that the benefits likely outweighed the harm.

  In contrast, in 9,811 moderate/severe cases in two RCTs, all-cause mortality was expected to decrease by 25 per 1,000, clinical improvement was expected to increase by 14 per 1,000, and the incidence of serious adverse events did not increase (decrease of 42 per 1,000). However, the overall certainty of evidence was very low, and the balance between benefit and harm was determined to be uncertain in patients with moderate/severe COVID-19.

- **Certainty of evidence**
  
  The certainty of evidence in all-cause mortality, clinical improvement, and serious adverse events was “very low,” “low,” and “very low,” respectively, in patients with mild COVID-19, and “very low,” “low,” “very low,” respectively, in patients with moderate/severe COVID-19. The inaccuracies in the net effect estimate across all outcomes were “Net benefit” in mild COVID-19 and “Likely net benefit” in moderate/severe COVID-19. From the above, it was ultimately determined that the overall evidence certainty was “low” in mild COVID-19 and “very low” in moderate/severe COVID-19.

- **Others (tolerability and feasibility)**
  
  Drug efficacy is likely to vary depending on the genotype of the mutant strain. Thus, indications should be judged based on the latest epidemiological information.

### CQ9-2 Should sotrovimab be administered to patients with COVID-19?

**Recommendation**

- We suggest sotrovimab administration to patients with mild COVID-19 who do not require oxygen (weak recommendation/low certainty of evidence: GRADE 2C).
- We have not made a clear recommendation on sotrovimab administration to patients with moderate COVID-19 requiring oxygen/hospitalization or patients with severe COVID-19 requiring mechanical ventilation/intensive care (no recommendation).

**Background** Sotrovimab is a monoclonal antibody that binds to a specific site different from the ACE2 receptor on the SARS-CoV-2 spike protein, exhibiting a neutralizing effect on SARS-CoV-2. The drug targets a highly conservative epitope shared by SARS-CoV-2 and SARS-CoV-1, which is inconsistent with the site of a genetic mutation previously reported in the mutant strain. Therefore, it is expected to exert similar effects on future mutant strains. Hence, this CQ has been raised as an essential issue to be addressed.
**Casirivimab / Imdevimab**

| 1200 mg (casirivimab 600 mg + imdevimab 600 mg) single-dose |
|---|
| **Favors control** | **Favors Medication use** | **Events per 1000 people** | **CoE** |
| Mortality | 22 | 15 | Very low |
| Clinical improvement | 959 | 888 | Low |
| SAE | 55 | 26 | Very low |
| Net effect estimate | 68 | 53 | Net benefit |

We suggest casirivimab/imdevimab administration to mild COVID-19 patients (GRADE 2C)

**Sotrovimab**

| 500 mg single-dose |
|---|
| **Favors control** | **Favors Medication use** | **Events per 1000 people** | **CoE** |
| Mortality | 4 | 0 | Very low |
| Clinical improvement | 943 | 889 | Moderate |
| SAE | 118 | 94 | Low |
| Net effect estimate | 94 | 91 | Likely net benefit |

We suggest sotrovimab administration to mild COVID-19 patients (GRADE 2C)

**Molnupiravir**

| 800 mg twice daily, up to 5 days |
|---|
| **Favors control** | **Favors Medication use** | **Events per 1000 people** | **CoE** |
| Mortality | 13 | 1 | Very low |
| Clinical improvement | 908 | 937 | Low |
| SAE | 96 | 69 | Very low |
| Net effect estimate | 65 | 61 | Net benefit |

We suggest molnupiravir administration to mild COVID-19 patients (GRADE 2C)

**Nirmatrelvir / Ritonavir**

| nirmatrelvir 300 mg + ritonavir 100 mg, twice daily, up to 5 days |
|---|
| **Favors control** | **Favors Medication use** | **Events per 1000 people** | **CoE** |
| Mortality | 11 | 0 | Very low |
| Clinical improvement | 937 | 92 | Low |
| SAE | 66 | 16 | Very low |
| Net effect estimate | 117 | 108 | Net benefit |

We suggest nirmatrelvir/ritonavir administration to mild COVID-19 patients (GRADE 2C)

---

Fig. 7. Recommendations of casirivimab/imdevimab, sotrovimab, molnupiravir, and nirmatrelvir/ritonavir for management for COVID-19 (CQ9-1, CQ9-2, CQ10, and CQ11). We suggest casirivimab/imdevimab, sotrovimab, molnupiravir, and nirmatrelvir/ritonavir administration to patients with mild COVID-19. Net effect estimates of casirivimab/imdevimab, sotrovimab, molnupiravir, and nirmatrelvir/ritonavir in patients with mild COVID-19 were calculated with the effects of each outcome, in which the importance of mortality was considered to be the same as those of other outcomes. Overall imprecisions across outcomes were assessed as “net benefit” in casirivimab/imdevimab, molnupiravir, and nirmatrelvir/ritonavir and “likely net benefit” in sotrovimab based on the magnitude of the point estimate and 95% confidence intervals of the calculated net effect estimates. Abbreviations: CoE, certainty of evidence; GRADE, Grades of Recommendation, Assessment, Development, and Evaluation; SAE, severe adverse events.

© 2022 The Authors. Acute Medicine & Surgery published by John Wiley & Sons Australia, Ltd on behalf of Japanese Association for Acute Medicine.
Recommendation rationale

- Balance between benefit and harm

In two RCTs72,74 with 1,409 patients with mild COVID-19, the administration of sotrovimab decreased all-cause mortality by 3 per 1,000, clinical symptom improvement by 47 per 1,000, and serious adverse events by 44 per 1,000 (Fig. 7). Sotrovimab administration to patients with mild COVID-19 positively affected each outcome. Meanwhile, in patients with moderate COVID-19, we did not obtain sufficient results to make a recommendation. In addition, no RCTs that examined the drug effects on patients with severe COVID-19 were detected. These results showed that the benefit of drug administration outweighed the harm in patients with mild COVID-19, while it was impossible to judge the balance of benefit and harm in patients with moderate to severe COVID-19.

- Certainty of evidence

For patients with mild COVID-19, the certainty of evidence regarding all-cause mortality, clinical improvement, and serious adverse events was judged to be “low,” “moderate,” and “low,” respectively. Considering the inaccuracy of the net effect estimate across all outcomes, the overall evidence certainty was determined to be “low.”

- Others (tolerability and feasibility)

Drug efficacy is likely to vary depending on the genotype of the mutant strain. Thus, indications should be judged based on the latest epidemiological information.

CQ10 Should molnupiravir be administered to patients with COVID-19?

Recommendation

- We suggest molnupiravir administration to patients with mild COVID-19 who do not require oxygen (weak recommendation/low certainty of evidence: GRADE 2C).
- We have not made a clear recommendation on molnupiravir administration to patients with moderate COVID-19 requiring oxygen/hospitalization and patients with severe COVID-19 requiring mechanical ventilation/intensive care (no recommendation).

Background Molnupiravir is a low-molecular-weight nucleotide prodrug of N-hydroxycytidine with activity against RNA viruses such as SARS-CoV-2. It is an agent that introduces mutations into viral RNA sequences by acting on RNA-dependent RNA polymerase, which is essential for self-replication of RNA viruses, and inhibits the growth of viruses. The drug was approved in Japan for the treatment of COVID-19 on December 24, 2021. It is important to reduce the pathological deterioration of patients at risk of severe disease, and this is considered to be of great clinical significance in the formulation of this CQ.

Recommendation rationale

- Balance between benefit and harm

There was one RCT75 with the adopted evidence (Fig. 7). In mild COVID-19 cases, a small effect is expected on all-cause mortality (decrease of 11 per 1,000) and improvement in clinical symptoms (increase of 27 per 1,000). There was no increase in the incidence of serious adverse events (decrease of 27 per 1,000). Therefore, for patients with mild COVID-19, it was determined that the benefit of molnupiravir administration outweighed the harm. There was no evidence for moderate or severe COVID-19, and it was deemed indeterminate.

- Certainty of evidence

The certainty of evidence for each outcome is “low.” The net effect estimate was considered and determined to be “low.”

- Others (tolerability and feasibility)

As the adopted evidence does not include omicron strains, caution should be exercised against their effects. In addition, the adopted RCTs were conducted on unvaccinated people, different from the current situation in Japan, where the vaccination rate is over 80%.

CQ11 Should nirmatrelvir/ritonavir be administered to patients with COVID-19?

Recommendation

- We suggest nirmatrelvir/ritonavir administration to patients with mild COVID-19 who do not require oxygen (weak recommendation/low certainty of evidence: GRADE 2C).
- We have not made a clear recommendation on nirmatrelvir/ritonavir administration to patients with moderate COVID-19 requiring oxygen/hospitalization or those with severe COVID-19 requiring mechanical ventilation/intensive care (no recommendation).

Background Nirmatrelvir/ritonavir is a combination of nirmatrelvir, which inhibits the main protease (Mpro) essential for viral replication of SARS-CoV-2, and ritonavir, which inhibits CYP3A4 that metabolizes it, and maintains effective blood concentration. It is important to reduce the deterioration of patients at risk of severe disease, and this is likely of great clinical significance in the formulation of CQs.

Recommendation rationale

- Balance between benefit and harm

One RCT with 2,246 cases was adopted (Fig. 7).76 In mild cases, nirmatrelvir/ritonavir was expected to decrease all-cause mortality by 11 per 1,000 and increase clinical improvement by 56 per 1,000. The incidence of serious...
adverse events did not increase (decrease of 50 per 1,000). Based on these data, the benefits outweighed harm in patients with mild COVID-19, whereas they were indeterminate in patients with moderate/severe COVID-19.

- Certainty of evidence
  The certainty of evidence for each outcome was “low” or “very low” in patients with mild COVID-19. Taking this into consideration, the overall certainty of evidence was determined to be “low” for patients with mild COVID-19.
- Others (tolerability and feasibility)
  As the adopted evidence does not include omicron strains, caution should be exercised against their effects. In addition, the adopted RCTs were conducted on unvaccinated people, different from the current situation in Japan, where the vaccination rate is over 80%.

RECOMMENDATIONS THAT STOPPED THE UPDATES

Two years have passed since the emergence of COVID-19. Some drugs that were initially expected to be effective against COVID-19 have been rejected, and several other novel drugs have been developed. Considering these clinical situations about COVID-19, the panel decided to stop the updates of two CQs (hydroxychloroquine [CQ3] and ciclesonide [CQ6]) in the updated version. Dated recommendations were as follows.1

CQ3 Should hydroxychloroquine be administered to patients with COVID-19? (last updated July 11, 2021)

Recommendation
• We recommend against hydroxychloroquine administration to all patients with COVID-19 (strong recommendation/moderate certainty of evidence: GRADE 1B).

CQ6 Should ciclesonide be administered by inhalation to patients with COVID-19? (last updated January 27, 2021)

Recommendation
• We have not made a clear recommendation on ciclesonide inhalation to all patients with COVID-19 (no recommendation).

ACKNOWLEDGMENTS

We would like to thank Editage (www.editage.jp) for English language editing and Mr. Tsuda (Davinci Medical Illustration Office) for medical illustration services.

DISCLOSURE

A PPROVAL OF THE research protocol: N/A
Informed consent: N/A.
Registry and the registration no. of the study/trial: N/A.
Animal studies: N/A.
Conflict of interest: The Japanese Society of Intensive Care Medicine and the Japanese Association for Acute Medicine jointly submitted this conflict of interest (COI) disclosure, based on the same policy issued by the Japanese Association of Medical Sciences. In accordance with these guidelines, organizations are only required to disclose COI related to associated companies or for-profit organizations as financial COI. We asked all members to submit their financial and academic COI for the past 3 years (2017, 2018, and 2019) in accordance with the current policy, as shown in the Supporting Information.

REFERENCES

1 Yamakawa K, Yamamoto R, Ishimaru G et al. Japanese rapid/living recommendations on drug management for COVID-19. Acute Med. Surg. 2021; 8: e664.
2 Yamakawa K, Yamamoto R, Terayama T et al. Japanese rapid/living recommendations on drug management for COVID-19: updated guidelines (September 2021). Acute Med. Surg. 2021; 8: e706.
3 Morgan RL, Florez I, Falavigna M et al. Development of rapid guidelines: 3. GIN-McMaster Guideline Development Checklist extension for rapid recommendations. Health Res. Policy Syst. 2018; 16: 63.
4 Fitch K, Bernstein SJ, Aguilar MD et al. The Rand/UCLA Appropriateness Method User’s Manual. Santa Monica, CA: RAND Corporation, 2001.
5 The Ministry of Health, Labor, and Welfare in Japan. Clinical Management of Patients with COVID-19: A Guide for Frontline Healthcare Workers.
6 Sterne JAC, Savovic J, Page MJ et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366: i4898.
7 Alper BS, Oettgen P, Kunnamo I et al. Defining certainty of net benefit: a GRADE concept paper. BMJ Open 2019; 9: e027445.
8 Alonso-Coello P, Oxman AD, Moher J et al. GRADE Evidence to Decision (EiD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: clinical practice guidelines. BMJ 2016; 353: i20.
9 Guyatt GH, Alonso-Coello P, Schünemann HJ et al. Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group. J. Clin. Epidemiol. 2016; 80: 3–7.

© 2022 The Authors. Acute Medicine & Surgery published by John Wiley & Sons Australia, Ltd on behalf of Japanese Association for Acute Medicine.
10 MAGIC MAGIC – (Making Grade the Irresistible Choice) New trustworthy guidelines, evidence summaries and decision aids that we can all use and share [homepage on the internet], 2021; [cited 6 Sep 2021]. Available from: https://magicvidence.org/

11 Lou Y, Liu L, Qiu Y. Clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: an exploratory randomized, controlled trial. Eur. J. Pharm. Sci. 2021; 157: 105631.

12 Ivashchenko AA, Dmitriev KA, Vostokova NV et al. AVIFAVIR for treatment of patients with moderate COVID-19: interim results of a phase II/III multicenter randomized clinical trial. Clin. Infect. Dis. 2021; 73: 531–4.

13 Balykova LA, Granovskaya MV, Zaslavskaya KY et al. Phase 3 Trial of Coronavirus (Favipiravir) in patients with mild to moderate COVID-19. SSRN 2020 in press.

14 Ruzhentsova T, Chukhliaev P, Khavkina D, et al. Phase 2 Trial of Coronavirus (Favipiravir) in patients with severe COVID-19. SSRN 2020 in press.

15 Udwadia ZF, Singh P, Barkate H et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int. J. Infect. Dis. 2020; 103: 62–71.

16 Zhao H, Zhang C, Zhu Q et al. Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: a multicenter, open-label, randomized trial. Int. Immunopharmacol. 2021; 97: 107702.

17 Chua H, Chow TS, Hor CP et al. Efficacy of early treatment with favipiravir on disease progression among high risk COVID-19 patients: a randomized, open-label clinical trial. Clin. Infect. Dis. 2021; ciab962.

18 Finberg RW, Ashraf M, Julg B et al. US201 Study: a phase 2, randomized proof-of-concept trial of favipiravir for the treatment of COVID-19. Open Forum. Infect. Dis. 2021; 8: ofab563.

19 Shenoy S, Munjal S, Youha SA et al. Favipiravir in adults with moderate to severe COVID-19: a phase 3 multicentre, randomized, double-blinded, placebo-controlled trial. medRxiv 2021 21265884.

20 Shinkai M, Tsushima K, Tanaka S et al. Efficacy and safety of favipiravir in moderate COVID-19 pneumonia patients without oxygen therapy: A randomized, phase III clinical trial. Infect. Dis. Ther. 2021; 10: 2489–509.

21 Holubar M, Subramanian A, Purington N et al. Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind, randomized, placebo-controlled, phase 2 trial. Clin. Infect. Dis. 2022; ciaa312.

22 Lowe DM, Brown LK, Chowdhury K et al. Favipiravir, lopinavir-ritonavir or combination therapy (FLARE): a randomised, double blind, 2x2 factorial placebo-controlled trial of early antiviral therapy in COVID-19. medRxiv 2022 22270775.

23 Bosaeed M, Alharbi A, Mahmoud E et al. Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial. Clin. Microbiol. Infect. 2022; 28: 602–8.

24 Beigel JH, Tomashek KM, Dodd LE et al. Remdesivir for the treatment of Covid-19 - final report. N. Engl. J. Med. 2020; 383: 1813–26.

25 Wang Y, Zhang D, Du G et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395: 1569–78.

26 Spinner CD, Gottlieb RL, Criner GJ et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA 2020; 324: 1048–57.

27 WHO Solidarity Trial Consortium, Pan H, Pet R et al. Repurposed antiviral drugs for Covid-19 interium WHO Solidarity Trial results. N. Engl. J. Med. 2021; 384: 497–511.

28 Ader F, Bouscambert-Duchamp M, Hites M et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect. Dis. 2022; 22: 209–21.

29 Gottlieb RL, Vaca CE, Paredes R et al. Early Remdesivir to prevent progression to severe Covid-19 in outpatients. N. Engl. J. Med. 2022; 386: 305–15.

30 Ali K, Azher T, Baqi M et al. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. CMAJ 2022; 194: E242–51.

31 Horby P, Lim WS, Emberson JR et al. Dexamethasone in hospitalised patients with Covid-19. N. Engl. J. Med. 2021; 384: 693–704.

32 Tomazini BM, Maia IS, Cavalcanti AB et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: The CoDEX randomized clinical trial. JAMA 2020; 324: 1307–16.

33 Angus DC, Derde L, Al-Beidh F et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA 2020; 324: 1317–29.

34 Dequinn PF, Heming N, Meziani F et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. JAMA 2020; 324: 1298–306.

35 Jeronimo CMP, Farias MEL, Val FFA et al. Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metocovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clin. Infect. Dis. 2020; ciaa1177.

36 Chen CP, Lin YC, Chen TC et al. A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and
tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19), PLoS One. 2020; 15: e0242763.

37 Tang X, Feng YM, Ni JX et al. Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: a multicenter, single-blind, randomized control trial. Respiration 2021; 100: 116–26.

38 Jamaati H, Hashemian SM, Farzanegan B et al. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial. Eur. J. Pharmacol. 2021; 897: 173947.

39 Corral-Gudino L, Bahamonde A, Arnaiz-Revillas F et al. GLUCOCOVID: a controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia. medRxiv 2020 2020.06.17.20133579.

40 Edalatifard M, Akhtari M, Salehi M et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. Eur. Respir. J. 2020; 56: 2002808.

41 Salvarani C, Massari M, Costantini M et al. Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia, A double-blind, randomised, placebo-controlled trial. Eur. Respir. J. 2022 2200025.

42 Rosas I, Bräu N, Waters M et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N. Engl. J. Med. 2021; 384: 1503–16.

43 Wang D, Fu B, Peng Z et al. Tocilizumab in patients with moderate or severe COVID-19: a randomised, controlled, open-label, multicenter trial. Front. Med. 2021; 15: 486–94.

44 Stone JH, Frigault MJ, Serling-Boyd NJ et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N. Engl. J. Med. 2020; 383: 2333–44.

45 Hermine O, Mariette X, Tharaux PL et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern. Med. 2021; 181: 32–40.

46 Salvarani C, Dolci G, Massari M et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: A randomized clinical trial. JAMA Intern. Med. 2021; 181: 24–31.

47 Salama C, Han J, Yau L et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N. Engl. J. Med. 2021; 384: 20–30.

48 Veiga VC, Prats JAGG, DLC F et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ 2021: n84.

49 Investigators TREMAP-CAP, LPG D, Gordon AC et al. Effectiveness of tocilizumab, sarilimumab, and anakinra for critically ill patients with COVID-19: the REMAP-CAP COVID-19 immune modulation therapy domain randomized clinical trial. medRxiv 2021 06.18.21259133.

50 RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021; 397: 1637–45.

51 Soin AS, Kumar K, Choudhary NS et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respir. Med. 2021; 9: 511–21.

52 Rutgers, A, Westerweel, PE, van der Holt B, et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients; 2021. https://ssrn.com/abstract=3834311

53 Talaschian M, Akhtari M, Mahmoudi M, et al. Tocilizumab failed to reduce mortality in severe COVID-19 patients: results from a randomized controlled clinical trial. Research Square; 2021. https://doi.org/10.21203/rs.3.rs-463921/v1

54 Rosas IO, Diaz G, Gottlieb RL et al. Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial. Intensive Care Med. 2021; 47: 1258–70.

55 Broman N, Feuth T, Vuorinen T et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomised, single-centre, open-label study. Clin. Microbiol. Infect. 2022; 28: 844–51.

56 Hermine O, Mariette X, Porcher R, CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 collaborative group. Eur. Respir. J. 2022; 60: 2102523.

57 Connors JM, Brooks MM, Scirba FC et al. Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial. JAMA 2021; 326: 1703–12.

58 Lopes RD, de Barros E, Silva PGM, Furtado RH et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet 2021; 397: 2253–63.

59 ATTACC Investigators; ACTIV-4a Investigators; REMAP-CAP Investigators et al. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N. Engl. J. Med. 2021; 385: 790–802.

60 Lemos ACB, do Espirito Santo DA, Salvetti MC et al. Therapeutic versus prophylactic anticoagulation for severe COVID-19: a randomized phase II clinical trial (HESACOVID). Thromb. Res. 2020; 196: 359–66.

61 Marcos-Jubilar M, Carmona-Torre F, Vidal R et al. Therapeutic versus prophylactic bemiparin in hospitalized patients with nonsevere COVID-19 pneumonia (BEMICOP study): an open-label, multicenter, randomized, controlled trial. Thromb. Haemost. 2022; 122: 295–9.
62 Spyropoulos AC, Goldin M, Giannis D et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: The HEP-COVID randomized clinical trial. AMA Intern. Med. 2021; 181: 1612–20.

63 REMAP-CAP Investigators; ACTIV-4a Investigators; ATTACC Investigators et al. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N. Engl. J. Med. 2021; 385: 777–89.

64 Sholzberg M, Tang GH, Rahhal H et al. Heparin for moderately ill patients with Covid-19. medRxiv 2021 2021.07.08.21259351.

65 Kalil AC, Patterson TF, Mehta AK et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N. Engl. J. Med. 2021; 384: 795–807.

66 Marconi VC, Ramanan AV, de Bono S et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir. Med. 2021; 9: 1407–18.

67 Ely EW, Ramanan AV, Kartman CE et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. bioRxiv 2021 10.11.21263897.

68 Horby P, Mafham M, Peto L et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2022; 399: 665–76.

69 Weinreich D, Sivapalasingam S, Norton T et al. REGEN-COV Antibody cocktail clinical outcomes study in Covid-19 outpatients. N. Engl. J. Med. 2021; 385: e81.

70 O’Brien MP, Forleo-Neto E, Sarkar N et al. Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: A randomized clinical trial. JAMA 2022; 327: 432–41.

71 Karakaya S, Mylonakis E, Menon VP et al. REGEN-COV® for treatment of hospitalized patients with Covid-19. medRxiv 2021 11.05.21265656.

72 Gupta A, Gonzalez-Rojas Y, Juarez E et al. Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: A randomized clinical trial. JAMA 2022; 327: 1236–46.

74 ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet Infect. Dis. 2022; 22: 622–35.

75 Jayk Bernal A, Gomes da Silva MM, Musungaire DB et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N. Engl. J. Med. 2022; 386: 509–20.

76 Hammond J, Leister-Tebbe H, Gardner A et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N. Engl. J. Med. 2022; 386: 1397–408.

SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article at the publisher’s web-site: Table S1 Task Force for the Japanese Rapid/Living recommendations on drug management for COVID-19.